XML 62 R36.htm IDEA: XBRL DOCUMENT v3.21.1
Summary of significant accounting policies - Narrative (Details)
$ in Thousands
12 Months Ended
Dec. 31, 2020
USD ($)
segment
Dec. 31, 2019
USD ($)
Research and Development Expense [Abstract]    
Reverse stock split ratio 0.1667  
Cash equivalents $ 0 $ 0
Restricted cash 100 100
Impairment losses 0 0
Deferred Offering Costs 0  
Accretion 0 0
Change in fair value of warrant liability 5,538  
Research and development expense $ 0 $ 0
Number of operating segments | segment 1  
Expected dividend yield 0.00%